{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER%2B%2C+HER2-%2C+Metastatic+Breast+Cancer", "query": { "condition": "ER+, HER2-, Metastatic Breast Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 217, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER%2B%2C+HER2-%2C+Metastatic+Breast+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-09T04:11:49.468Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03691493", "title": "Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Positive", "HER2/Neu Negative", "Metastatic Breast Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Progesterone Receptor Positive", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-02-08", "completion_date": "2022-10-13", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-10-09T04:11:49.468Z", "location_count": 10, "location_summary": "Atlanta, Georgia • Augusta, Georgia • Columbus, Georgia + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03691493" }, { "nct_id": "NCT01957514", "title": "Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Stage IV Breast Cancer AJCC v6 and v7", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 31, "start_date": "2013-10-28", "completion_date": "2018-06-30", "has_results": false, "last_update_posted_date": "2021-09-30", "last_synced_at": "2026-10-09T04:11:49.468Z", "location_count": 2, "location_summary": "Seattle, Washington • Tacoma, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01957514" }, { "nct_id": "NCT04072952", "title": "A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Vepdegestrant", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arvinas Estrogen Receptor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2019-09-22", "completion_date": "2026-03-05", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-09T04:11:49.468Z", "location_count": 16, "location_summary": "Palo Alto, California • San Francisco, California • Santa Monica, California + 12 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04072952" }, { "nct_id": "NCT00630032", "title": "Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "epirubicin hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNICANCER", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 762, "start_date": "2007-09", "completion_date": "2020-09-03", "has_results": true, "last_update_posted_date": "2024-02-21", "last_synced_at": "2026-10-09T04:11:49.468Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Denver, Colorado • Jacksonville, Florida + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Cedar Rapids", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00630032" }, { "nct_id": "NCT06938711", "title": "A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Elacestrant", "type": "DRUG" }, { "name": "Onapristone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Context Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2023-06", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-10-09T04:11:49.468Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06938711" }, { "nct_id": "NCT06666439", "title": "Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Invasive Lobular Carcinoma (mILC)" ], "interventions": [ { "name": "circulating tumor DNA (ctDNA)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Julia Foldi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2024-12-12", "completion_date": "2029-10-31", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-10-09T04:11:49.468Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06666439" }, { "nct_id": "NCT02260531", "title": "Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Brain Tumor - Metastatic" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2014-11", "completion_date": "2020-03-17", "has_results": true, "last_update_posted_date": "2021-05-20", "last_synced_at": "2026-10-09T04:11:49.468Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02260531" }, { "nct_id": "NCT03250676", "title": "Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer", "Estrogen-receptor Positive Breast Cancer", "Cancer, Breast", "Breast Cancer Female", "Breast Adenocarcinoma", "Estrogen Receptor Positive Tumor", "ER Positive" ], "interventions": [ { "name": "H3B-6545", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 151, "start_date": "2017-08-23", "completion_date": "2023-10-26", "has_results": true, "last_update_posted_date": "2025-02-25", "last_synced_at": "2026-10-09T04:11:49.468Z", "location_count": 23, "location_summary": "Goodyear, Arizona • Los Angeles, California • San Francisco, California + 18 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03250676" }, { "nct_id": "NCT01441947", "title": "Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2011-10", "completion_date": "2019-08-09", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-10-09T04:11:49.468Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01441947" }, { "nct_id": "NCT03566485", "title": "Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Estrogen Receptor-positive", "HER2/Neu Negative" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Idasanutlin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2018-07-10", "completion_date": "2020-12-10", "has_results": true, "last_update_posted_date": "2021-08-11", "last_synced_at": "2026-10-09T04:11:49.468Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03566485" } ] }